Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

SELL
$0.13 - $76.84 $2,283 - $1.35 Million
-17,564 Closed
0 $0
Q1 2022

May 11, 2022

BUY
$61.48 - $73.72 $77,526 - $92,960
1,261 Added 7.73%
17,564 $1.28 Million
Q4 2021

Feb 10, 2022

SELL
$53.63 - $62.52 $122,437 - $142,733
-2,283 Reduced 12.28%
16,303 $1.02 Million
Q3 2021

Nov 15, 2021

BUY
$59.17 - $69.31 $503,891 - $590,243
8,516 Added 84.57%
18,586 $1.1 Million
Q2 2021

Aug 06, 2021

SELL
$61.91 - $67.42 $18,077 - $19,686
-292 Reduced 2.82%
10,070 $673,000
Q1 2021

May 12, 2021

SELL
$59.34 - $66.74 $566,697 - $637,367
-9,550 Reduced 47.96%
10,362 $654,000
Q4 2020

Feb 12, 2021

BUY
$57.74 - $65.43 $496,564 - $562,698
8,600 Added 76.03%
19,912 $1.24 Million
Q3 2020

Nov 13, 2020

BUY
$57.43 - $63.64 $7,695 - $8,527
134 Added 1.2%
11,312 $682,000
Q2 2020

Aug 06, 2020

SELL
$54.82 - $64.09 $160,896 - $188,104
-2,935 Reduced 20.8%
11,178 $657,000
Q1 2020

May 12, 2020

BUY
$46.4 - $67.43 $17,956 - $26,095
387 Added 2.82%
14,113 $787,000
Q4 2019

Jan 31, 2020

BUY
$49.21 - $64.19 $40,795 - $53,213
829 Added 6.43%
13,726 $881,000
Q3 2019

Nov 08, 2019

SELL
$42.77 - $50.71 $57,012 - $67,596
-1,333 Reduced 9.37%
12,897 $654,000
Q2 2019

Aug 06, 2019

BUY
$44.62 - $49.34 $73,087 - $80,818
1,638 Added 13.01%
14,230 $645,000
Q1 2019

Apr 29, 2019

BUY
$45.12 - $53.8 $26,620 - $31,742
590 Added 4.92%
12,592 $601,000
Q4 2018

Feb 07, 2019

BUY
$48.76 - $63.23 $2,681 - $3,477
55 Added 0.46%
12,002 $624,000
Q2 2018

Aug 09, 2018

SELL
$50.53 - $62.98 $88,023 - $109,711
-1,742 Reduced 12.73%
11,947 $661,000
Q1 2018

May 14, 2018

SELL
$59.92 - $68.98 $2,037 - $2,345
-34 Reduced 0.25%
13,689 $866,000
Q4 2017

Feb 02, 2018

BUY
$59.94 - $65.35 $822,556 - $896,798
13,723
13,723 $841,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $125B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Meristem Family Wealth, LLC Portfolio

Follow Meristem Family Wealth, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Meristem Family Wealth, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Meristem Family Wealth, LLC with notifications on news.